Open Access Open Access  Restricted Access Subscription or Fee Access

A STUDY ON IMPACT AND OUTCOMES OF PHARMACOVIGILANCE AND ITS IMPLICATIONS, PRACTICES OVER ADR IDENTIFICATION, REPORTING AND MONITORING IN PROMOTION OF RATIONAL DRUG USAGE.

Mekkanti Manasa Rekha

Abstract


The present study reports on impact of pharmacovigilance and drug safety monitoring practices in promotion of rational drug usage in General Medicine Department of ESI hospital with an objective of identification and reporting of adverse drug reactions. It is a prospective, observational study & was conducted for a period period of 8 months from Jan 2022 to Aug 2022. A sample size of 126 patients were randomly opted for this study, out of which 58 (sample size) were analysed for potential drug interactions and were also selected for comparison of results. The details of patient’s medication therapy were collected from patients through personal interview, case sheets, treatment charts and data collection forms. Data collected during the study included demographics of the patients who encountered the ADRs, diagnosis, co- morbidities, treatment, information regarding previous allergies and other medicines taken by the patient. During the study period, a total of 58 ADRs were reported by CPs, out of which, the most common organ system affected was GIT 23(39.64), Therapeutic drug class most implicated to cause ADRs was Antihypertensives 12(20.68%), As per the Rawlins and Thompson classification of ADRs out of 58 reported ADRs 43(74.13%) are type A reactions and 15(25.86%) are type B reactions. The most commonly reported ADR was Acidity 8(13.79%). On evaluation of severity of reported ADRs using Hartwig’s severity scale, majority of ADRs 43(74.13%) were mild in nature. Upon causality assessment of reported ADRs using WHO probability scale, majority of ADRs 22(37.93%) were rated as ‘Possible’ and as per the Naranjo scale, majority of reported ADRs 35(60.34%) were rated as ‘Possible’. The Present Study concludes that Detection of adverse drug reaction, the harmful effects of drugs to the patient were prevented and minimized byproviding the Physician and other, Healthcare Professionals with the information’s regarding identified problems and reporting them to respected authorities.


Full Text:

PDF

References


A Text Book on Clinical Pharmacy Overview Product Id: 159927-1337395-naned-t0-hari-reg-ind-diy (ISBN: 9781649830067) Published and Released by Notion Press Books STORES

Mekkanti Manasa Rekha, A. Bharath Kumar Prospective study on implementation of clinical pharmacy services to general medicine department in a tertiary care hospital published in journal of Pharma research, Research article available online through 2016 5(8) :191-198.

A. Bharath Kumar, Kumar, M.Saipavan, M.Gobinath. A Review on scope importance and future needs of clinical pharmacy practice in India. International journal of current trends in Pharmaceutical research.2015, 3(3): 916-923.

American College of Clinical Pharmacy. Pharmacotherapy 2008-28 (6), 816–817.

American College of Clinical Pharmacy. The Definition of Clinical Pharmacy. Pharmacotherapy 2008; 28(6):816-817.

Guidelines for Preparing Core Clinical Safety Information on Drugs - Report of CIOMS Working Group III. Geneva, WHO, 1995. Available from: URL:http://www.whoumc.org/DynPage.aspxid=226

L. Harmark, A. C. van Grootheest. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 20014;64:743-52.

Pirmohamed M, Dodoo A, Winstanley P. Pharmacovigilance in developing countries. BMJ 2007;335:462.

Stephens M. The history of pharmacovigilance. In: Talbot J, Waller P, editors. A text book of Stephen’s detection of new adverse reactions. 5th ed. British library; 2004. p.8- 10.

WHO. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva. World Health Organization 2006: p 21. Available from: URL:http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigila nce_B.pdf

Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. JPRHC 2010 Jan;2(1):127-34.

Palaian S, Mishra P, Izham M, Celen A. Community pharmacovigilance in Nepal: a guide for community pharmacists. A publication of the Regional Pharmacovigilance Centre 2008, Manipal Teaching Hospital, Pokhara, Nepal. Available from: URL: from: URL: http://www.haiap.org/wordpress/wp-content/uploads/2008/08/PV-booklet20thNov.pdfhttp://www.haiap.org/wordpress/wp-content/uploads/2008/08/PV-booklet20thNov.pdf

ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. Am J Health Syst Pharm 1995; 52:417-419.

Marc A. Riedl, M.D., and Adrian M. Casillas, M.D. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003 1; 68(9):1781-1791.

Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. ClinPharmacolTher. 1977; 21:247–54.

MedWatch: The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/.

Naranjo CA et al. A method for estimating the probability of adverse drug reactions. ClinPharmacolTher. 1981; 30:239245

Center for Drug Evaluation and Research. Drug Interactions: What You Should. FDA; https://www.fda.gov/drugs/resources-you/drug-interactions-what-you-shouldkno

National Coordinating Council for Medication Error Reporting and Prevention. About medication errors. Available at: http://www.nccmerp.org/aboutMedErrors.html. Accessed on November 6, 2011.

sanvidhan G suke, Role of pharmacovigilance in India: an overview:: https://doi.org/10.5210/ojphi.v7i2.5595


Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Pharmacology